

INPLASY

Postoperative eradication of *Helicobacter pylori* in patients with gastric cancer can bring survival benefits

INPLASY202560047

doi: 10.37766/inplasy2025.6.0047

Received: 11 June 2025

Published: 11 June 2025

Liu, BY; Jia, ZB; Ding, L.

Corresponding author:

Lei Ding

jiazhibo1995@163.com

Author Affiliation:Capital Medical University Affiliated
Beijing Shijitan Hospital.**ADMINISTRATIVE INFORMATION****Support** - None.**Review Stage at time of this submission** - Data analysis.**Conflicts of interest** - None declared.**INPLASY registration number:** INPLASY202560047**Amendments** - This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 11 June 2025 and was last updated on 11 June 2025.**INTRODUCTION**

Review question / Objective Will the eradication of *Helicobacter pylori* after gastric cancer surgery bring any survival benefits to patients?

Condition being studied Gastric cancer.**METHODS****Participant or population** Patients with gastric cancer need to undergo surgical treatment and are positive for *Helicobacter pylori*.**Intervention** Post-operative treatment for *Helicobacter pylori* infection.**Comparator** OS、DFS.**Study designs to be included** RCT, Prospective study, retrospective study.

Eligibility criteria (1) Patients diagnosed were with gastric cancer and underwent surgical treatment. The presence of *Helicobacter pylori* was detected after surgery. There were no restrictions on patient age, gender, etiology, disease stage, or surgical approach. Surgical methods could include open surgery, laparoscopic surgery, or others. (2) The intervention in the experimental group was the administration of anti-*Helicobacter pylori* therapy after surgery. (3) The primary outcome measures were overall survival (OS) and disease-free survival (DFS). The secondary outcome measures included gastric cancer-specific mortality, gastric cancer recurrence, and overall mortality. (4) Hazard ratios (HRs), corresponding 95% confidence intervals (CIs) and survival outcomes were reported, or other data for the reconstruction of survival data, such as Kaplan–Meier curves.

Information sources Pubmed Embase Cochrane Library.**Main outcome(s)** HR and 95%CI DFS OS.

Quality assessment / Risk of bias analysis NOS
egger test begg test.

Strategy of data synthesis Use the Stata data
analysis software for data merging.

Subgroup analysis Subgroup analysis was
conducted based on factors such as the country,
inclusion time, and age.

Sensitivity analysis Remove each included
literature one by one for the purpose of conducting
a sensitivity analysis.

Country(ies) involved China, korea.

Keywords gastric cancer; surgery; Helicobacter
pylori eradication.

Contributions of each author

Author 1 - Binyan Liu.

Author 2 - ZhiBo Jia.

Author 3 - Lei Ding.